Scarica l'app Stockscreener
1.2299
0.16%
0.002
Bionexus Gene Lab Corp Borsa (BGLC) Ultime notizie
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence - FinancialContent
Ruanyun Edai Technology Announces Definitive Agreement to License Cogni AI to BioNexus Gene Lab for Malaysian Healthcare Market - Quiver Quantitative
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab - GlobeNewswire Inc.
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
12 Industrials Stocks Moving In Friday's Pre-Market Session - Benzinga
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
11 Industrials Stocks Moving In Wednesday's After-Market Session - Benzinga
Jook Yuen Low Net Worth (2026) - GuruFocus
Set Fui Chong Net Worth (2026) - GuruFocus
Fidelion Diagnostics Pte. Ltd. Net Worth (2026) - GuruFocus
Bin Abdul Hamid Muhammad Azrul Net Worth (2026) - GuruFocus
BioNexus Gene Lab Revenue Collapses 97% in Q2 as Major Customer Lost - minichart.com.sg
BioNexus Gene Lab Corp (BGLC) CEO reports 338,709-share award and 11.5% stake - Stock Titan
BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares - Stock Titan
BioNexus Gene Lab Corp (BGLC) director receives 32,258-share fully vested award - Stock Titan
BioNexus Gene Lab Corp (BGLC) director receives 32,258-share equity award - Stock Titan
BioNexus Gene Lab Corp (BGLC) CFO receives 96,774-share equity award - Stock Titan
BioNexus Gene Lab Corp (BGLC) director granted 16,129-share fully vested stock award - Stock Titan
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury - Yellow.com
BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd - Bitget
Fidelion Diagnostics reports 392,329 BioNexus Gene Lab Corp (NASDAQ: BGLC) shares - Stock Titan
BioNexus Gene Lab Corp (BGLC) Stock News Today - TradingKey
BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd - Bitget
BioNexus Gene Lab (BGLC) Surges 8.3% to $1.43: Can Momentum Break the $1.50 Ceiling?Volume Climax - dars.gov.et
BioNexus Gene Lab (BGLC) director discloses 1,261 common shares in Form 3 - Stock Titan
BioNexus Gene Lab (BGLC) director files Form 3 with zero shares - Stock Titan
BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioNexus Says VitaGuard Blood Tests Could Cost Under $300 - Stock Titan
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit - GlobeNewswire
BGLC|BioNexus Gene Lab Corp|Price:1.370|Chg%:-0.140 - TradingKey
BGLC|BioNexus Gene Lab Corp|Price:1.450|Chg%:-0.060 - TradingKey
BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC - TradingView
BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioNexus Gene Lab Corp (BGLC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BGLC|BioNexus Gene Lab Corp|Price:1.510|Chg%:-0.050 - TradingKey
BioNexus Gene Lab Corp (BGLC) Cash Flow - TradingKey
TradingKey - TradingKey
BioNexus Gene Lab Corp (BGLC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BGLC|BioNexus Gene Lab Corp|Price:1.613|Chg%:-0.027 - TradingKey
BioNexus Gene Lab Corp (BGLC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
4.20%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):